Grifols, S.A.(GRFS)Earnings, Financials & Key Ratios
GRFS•NASDAQ
$7.21
11.1× P/E·Price updated Jul 7, 2026
AboutGrifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuumfrom prevention, screening, diagnosis, and prognosis to disease and treatment monitoringto serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.Show more
- Revenue$7.23B+0.2%
- EBITDA$1.62B-0.6%
- Net Income$386M+146.1%
- EPS (Diluted)0.57+147.8%
- Gross Margin35.7%-7.9%
- EBITDA Margin22.41%-0.8%
- Operating Margin16.43%-0.6%
- Net Margin5.34%+145.6%
- ROE4.77%+144.8%
GRFS Price & Volume
Grifols, S.A. (GRFS) stock price & volume — 10-year historical chart
Loading chart...
Persistent Margin Compression Clouds Structural Debt Burden
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Decelerating
Profitability:Strained
Financial:Strained
Cash Flow:Mixed
Primary Risk:High leverage and governance
Key Thesis Takeaways
- Grifols faces a challenging outlook characterized by decelerating revenue growth, which contracted 3.2% year-over-year in 2026Q1, and persistent margin compression that limits operational flexibility.
- The company's heavy reliance on a $9.7 billion debt load, coupled with significant goodwill accounting for $10.6 billion of total assets, creates substantial financial risk.
- Investors should remain cautious as the firm struggles to convert accounting profits into consistent free cash flow, evidenced by the volatile FCF margin that swung from -12.5% in 2024Q1 to 21.0% in 2024Q4.
Verdict Logic
the company's high leverage, evidenced by a debt-to-EBITDA ratio of 26.98 in 2026Q1, combined with declining top-line growth, suggests significant downside risk for equity holders.
GRFS Growth Metrics
Grifols, S.A. (GRFS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years6.27%
5 Years6.24%
3 Years6.02%
TTM1.02%
Profit CAGR
10 Years-3.16%
5 Years-8.99%
3 Years27.79%
TTM112.86%
EPS CAGR
10 Years-3.09%
5 Years-4.83%
3 Years22.51%
TTM114.86%
Return on Capital
10 Years7.1%
5 Years5.06%
3 Years5.61%
Last Year6.42%
GRFS Recent Earnings
Grifols, S.A. (GRFS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/12 qtrs (17%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.17+7.3%
$0.16
Rev
$2.0B-1.4%
$2.0B
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$0.29-0.3%
$0.29
Rev
$2.3B-0.2%
$2.3B
Q1 2026
Feb 25, 2026Metric
Actual
Est
EPS
$0.29-0.3%
$0.29
Rev
$2.3B-0.2%
$2.3B
Q4 2025
Nov 4, 2025Metric
Actual
Est
EPS
$0.22-9.6%
$0.24
Rev
$2.2B+1.5%
$2.2B
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.17vs $0.16+7.3% | $2.0Bvs $2.0B-1.4% |
| Q1 2026 | Feb 26, 2026 | $0.29vs $0.29-0.3% | $2.3Bvs $2.3B-0.2% |
| Q1 2026 | Feb 25, 2026 | $0.29vs $0.29-0.3% | $2.3Bvs $2.3B-0.2% |
| Q4 2025 | Nov 4, 2025 | $0.22vs $0.24-9.6% | $2.2Bvs $2.2B+1.5% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Grifols, S.A. (GRFS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $7.21 | $6.1B | 11.07 | 0.2% | 5.34% | 4.77% | 2.86% | |
| $15.95 | $49.84B | 40.39 | 4.28% | 4.25% | 2.62% | — | |
| $353.87 | $14.47B | 20.67 | 0.33% | 14.57% | 34.48% | — | |
| $15.55 | $1.65B | -2.27 | — | — | -866.46% | — | |
| $12.03 | $1.06B | 30.85 | 60.93% | 17.43% | 3.45% | — | |
| $10.99 | $2.31B | 9.08 | 94.1% | -51.71% | — | — |
Compare GRFS vs Peers
Grifols, S.A. (GRFS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when GRFS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
GRFS Frequently Asked Questions
Grifols, S.A. (GRFS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Grifols, S.A.'s revenue?
Grifols, S.A. (GRFS) reported $7.45B in revenue for fiscal year 2025. This represents a 1321% increase from $524.3M in 2005.
How fast is Grifols, S.A. growing?
Grifols, S.A. (GRFS) grew revenue by 0.2% over the past year. Growth has been modest.
Is GRFS profitable?
Yes, Grifols, S.A. (GRFS) is profitable, generating $415.6M in net income for fiscal year 2025 (5.3% net margin).
Dividend & Returns
Does GRFS pay dividends?
Yes, Grifols, S.A. (GRFS) pays a dividend with a yield of 2.86%. This makes it attractive for income-focused investors.
What is GRFS's return on equity?
Grifols, S.A. (GRFS) has a return on equity (ROE) of 4.8%. This is below average, suggesting room for improvement.
What is Grifols, S.A.'s free cash flow?
Grifols, S.A. (GRFS) generated $744.5M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.